SCHEMBL18285293

SCHEMBL18285293

CCc1nccn1-c1cc(C(=O)NC(C)(C)C)cc(-c2ccc(F)cc2)c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
P2RY14 Q15391 1/20 0.40
ANO1 Q5XXA6 1/20 0.38
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
NAMPT P43490 1/20 0.38
P2RX3 P56373 1/20 0.37
P2RX2 Q9UBL9 1/20 0.37
THRB P10828 2/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
FGFR1 P11362 2/20 0.36
TP53 P04637 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
CNR2 P34972 1/20 0.35
RIPK1 Q13546 1/20 0.35
DGAT2 Q96PD7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20921559 0.91 ALDH1A1 (0.39) P2RY14PDE4APDE4BPDE4CPDE4D
SCHEMBL18285366 0.90 WDR5 (0.38) ANO1PDE4APDE4BPDE4CPDE4D
SCHEMBL18285311 0.90 MAPT (0.42) P2RY14ANO1PDE4APDE4BPDE4C
SCHEMBL18285367 0.86 RAF1 (0.43) P2RY14ANO1NAMPTTHRBLMNA
SCHEMBL18285309 0.85 P2RY14 (0.41) P2RY14ANO1THRBLMNAMAPT
SCHEMBL18285343 0.84 P2RY14 (0.40) P2RY14ANO1THRBLMNAMAPT
SCHEMBL20921546 0.84 P2RY14 (0.38) P2RY14ANO1P2RX3P2RX2THRB
SCHEMBL18285360 0.83 P2RY14 (0.40) P2RY14ANO1PDE4APDE4BPDE4C
SCHEMBL18285285 0.82 P2RY14 (0.39) P2RY14ANO1THRBLMNAMAPT
SCHEMBL18389419 0.82 MAPT (0.40) ANO1NAMPTTHRBLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107531642-B Imidazole derivatives 豪夫迈·罗氏有限公司 2021-06-22 CN claimed
EP-3303299-B1 IMIDAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2019-04-24 EP claimed
EP-3303299-A1 IMIDAZOLE DERIVATIVES H. Hoffnabb-La Roche Ag (CH) 2018-04-11 EP claimed
WO-2016193235-A1 IMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2016-12-08 WO claimed
CN-107531642-B Imidazole derivatives 豪夫迈·罗氏有限公司 2021-06-22 CN disclosed
EP-3303299-B1 IMIDAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2019-04-24 EP disclosed
US-10029989-B2 Imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2018-07-24 US disclosed
US-10029989-B2 Imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2018-07-24 US disclosed
US-20180118692-A1 IMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2018-05-03 US disclosed
US-20180118692-A1 IMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2018-05-03 US disclosed
EP-3303299-A1 IMIDAZOLE DERIVATIVES H. Hoffnabb-La Roche Ag (CH) 2018-04-11 EP disclosed
WO-2016193235-A1 IMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2016-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118692-A1 IMIDAZOLE DERIVATIVES DRD3, GABRR3, DRD4 P2RY14 3572/4885ANO1 1134/4885PDE4A 2694/4885
US-10029989-B2 Imidazole derivatives DRD3, GABRR3, DRD4 P2RY14 3572/4885ANO1 1134/4885PDE4A 2694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.